Immuron Limited announced the submission of the Clinical Study Report for its Phase 2 clinical trial of Travelan® (IMM-124E) to the FDA, which demonstrated statistically significant immunological and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback